Improving Rheumatoid Arthritis Care: Understanding the Latest Approvals and Treatment Strategies

Rheumatoid arthritis (RA) persists as an inflammatory condition with substantial morbidity. While the wide variety of RA treatment options continues to grow (two additional agents were approved in the last two years), rheumatologists remain challenged with staying up-to-date on the latest clinical trial data. Other gaps in RA care relate to the lack of treat-to-target (T2T) goals and shared decision-making (SDM), both of which are now important components of modern RA management. To best address these knowledge and practice gaps, it is critical that rheumatologists partake in continuing education.

“Improving Rheumatoid Arthritis Care: Understanding the Latest Approvals and Treatment Strategies,” will provide rheumatologists with current evidence regarding treatment goals and therapies for RA as well as strategies for effectively communicating with patients about their RA care.

Target Audience

The intended audience for this activity is rheumatologists, the main care providers for patients with RA.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Implement strategies to facilitate shared decision-making to establish treat-to-target (T2T) goals
  • Evaluate the safety and efficacy data for newer RA agents
  • Incorporate the latest RA therapies into appropriate treatment plans

 

This program is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course opens: 
12/15/2020
Course expires: 
12/15/2021
Rating: 
5

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Please login or register to take this course.